The physiopathology of lipoprotein (a)

Frontiers in Bioscience - Scholar

Volumn 2 S, Issue 3, 2010, Pages 866-875

  Galvano, Fabio ^a   Malaguarnera, Michele ^a   Vacante, Marco ^a   Motta, Massimo ^a   Russo, Cristina ^a   Malaguarnera, Giulia ^a   D'Orazio, Nicolantonio ^b   Malaguarnera, Lucia ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Adhesion molecules; Atherothrombosis; Fibrinolysis; Lipoprotein(a); Review

Indexed keywords

CELL ADHESION MOLECULE; FIBRINOGEN; FIBRONECTIN; ISOPROTEIN; LIPOPROTEIN A; PLASMINOGEN; TRANSFORMING GROWTH FACTOR BETA;

ATHEROSCLEROSIS; BLOOD; CHEMISTRY; FIBRINOLYSIS; GENETICS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; REVIEW;

ATHEROSCLEROSIS; CELL ADHESION MOLECULES; FIBRINOGEN; FIBRINOLYSIS; FIBRONECTINS; HUMANS; LIPOPROTEIN(A); PLASMINOGEN; PROTEIN ISOFORMS; REFERENCE VALUES; TRANSFORMING GROWTH FACTOR BETA;

EID: 77956624711     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. K Berg. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand. 59, 369-82 (1963)
2. PO Kwiterovich, J Coresh, HH Smith, et al Comparison of the plasma levels of apolipoproteins B and A-l, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol. 69, 1015-21 (1992) (Pubitemid 23058996)
3. GM Fless, ME ZumMallen, and AM Scanu. Physicochemical properties of apolipoprotein(a) and lipoprotein(a) derived from the dissociation of human plasma lipoprotein (a). J Biol Chem. 261, 8712-18 (1986) (Pubitemid 17205067)
4. SM Marcovina, ML Koschinsky. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol. 82, 57U-66U(1998) (Pubitemid 29047617)
5. S Chitayat, V Kanelis, ML Koschinsky, SP Smith. Nuclear magnetic resonance (NMR) solution structure, dynamics, and binding properties of the kringle IV type 8 module of apolipoprotein(a). Biochemistry. 20, 1732-42 (2007)
6. MJ Callow, EM Rubin. Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo. J Biol Chem. 270, 23914-17 (1995).
7. SP McCormick, JK Ng, S Laylor, LM Flynn, RE Hammer, SG Young. Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). Proc Natl Acad Sci. 92, 10147-51. (1995)
8. J Guevara Jr, NV Valentinova, O Garcia, AM Gotto, CY Yang, S Legal, J Gaubatz, JL Sparrow. Interaction of apolipoprotein [a] with apolipoprotein B-100 Cys3734 region in lipoprotein [a] is confirmed immunochemically. J Protein Chem. 15, 17-25 (1996) (Pubitemid 26065970)
9. MJ McQueen, S Hawken, X Wang Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, S Yusuf. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INLERHEARL study): a case-control study. Lancet. 372, 224-33 (2008) (Pubitemid 351978112)
10. C Lackner, JC Cohen, HH Hobbs. Molecular definition of the extreme size polymorphism in apolipoprotein(a). HumMol Genet. 2, 933-40 (1993) (Pubitemid 23216624)
11. G Lippi, G Guidi. Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci. 40:1-42 (2003) (Pubitemid 36250229)
12. K Berg. Risk factor variability and coronary heart disease. Acta Genet Med. 39:15-24 (1990) (Pubitemid 20328682)
13. A Edjème-Aké, R Garnotel, S Vallée-Polneau, E Anglés-Cano, D Monnet, P Gillery. Relationship between apo(a) length polymorphism and lipoprotein(a) concentration in healthy Ivorian subjects with single or double apo(a) isoforms. Clin Biochem. 41:1039-43. (2008)
14. H Dieplinger, C Lackner, FKronenberg, C Sandholzer, Lhotta K, Hoppichler F, Graf H, König P. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest. 91:397-401 (1993) (Pubitemid 23064119)
15. R Guerra, Z Y.u., S Marcovina, R Peshock, JC Cohen, HH Hobbs. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation. 111:1471-9(2005) (Pubitemid 40470640)
16. C Sandholzer, E Boerwinkle, N Saha, MC Long, G Utermann. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest. 3:1040-6(1992)
17. GX Shen. Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells. Mol Cell Biochem. 246:69-74 (2003) (Pubitemid 36798724)
18. J Zhang, S Ren, GX Shen. Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis. 2:299-308 (2000) (Pubitemid 30336542)
19. C Edelstein, D Pfaffrnger, J Hinman, E Miller, G Lipkind, S Lsimikas, C Bergmark, GS Getz, JL Witztum, AM Scanu. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential proinflammatory properties to human apolipoprotein (a). J Biol Chem. 278: 52841-417 (2003)
20. M Malaguarnera, Vacante M, Motta M., Malaguarnera M, Li Volti G, Galvano F. Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism. 58, 1618-23. 2009
21. DJ Rader, W Cain, LA Zech, D Usher, HB Brewer. "Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production,". J. Clin. Invest. 2: 443-7 (1993) (Pubitemid 23064127)
22. BL Knight, YF Perombelon, AK Soutar, DP Wade, M Seed. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis. 87: 227-37 (1991)
23. CL Scholtz, A Lingenhel, R Hillermann, IA Stander, JA Kriek, MP Marais, HJ Odendaal, HG Kraft, G Utermann, MJ Kotze. Lipoprotein(a) determination and risk of cardiovascular disease in South African patients with familial hypercholesterolemia. S Afr Med J. 4:374-8 (2000) (Pubitemid 30303554)
24. SS Anand, EA Enas, J Pogue, S Haffner, T Pearson, S Yusuf. Elevated lipoprotein(a) levels in South Asians in North America. Metabolism. 2:182-4 (1998) (Pubitemid 28084153)
25. H Akita, M Matsubara, H Shibuya, H Fuda, H Chiba. Effect of ageing on plasma lipoprotein(a) levels. Ann Clin Biochem. 3:237-40 (2002) (Pubitemid 34494213)
26. J Hoover-Plow, E Hart, Y Gong, A Shchurin, TA Schneeman. Physiological Function for Apolipoprotein(a): A natural regulator of the inflammatory response. Exp Biol Med. 234:28-34 (2009)
27. BF Asztalos, PS Roheim, RL Milani, M Lefevre, JR McNamara, KV Horvath, EJ Schaefer. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vase Biol. 12:2670-6 (2000)
28. T Soulat, S Loyau, V Baudouin, V Durlach, P Gillery, R Garnotel, C Loirat, Anglès-Cano E. Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin-a study with individual plasmas presenting natural variations of Lp(a). J Thromb Haemost. 1:121-7 (1999) (Pubitemid 29368784)
29. L Hervio, MJ Chapman, J Thillet, S Loyau, Anglès-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood. 2:392-7 (1993) (Pubitemid 23206101)
30. F Kronenberg, MF Kronenberg, S Kiechl, E Trenkwalder, P Santer, F Oberhollenzer, G Egger, G Utermann, J Willeit. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 100:1154-60 (1999) (Pubitemid 29426589)
31. XJ Lou, NW Boonmark, FT Horrigan, IL Degen, RM Lawn. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA. 21:12591-5 (1998) (Pubitemid 28483809)
32. J Pineda, F Marin, P Marco, V Roldân, J Valencia, JM Ruiz-Nodar, F Sogorb, GY Lip. Premature coronary artery disease in young (age < 45) subjects: Interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol. 136:222-5. (2008)
33. DE Barre. The molecular nature and consequences of lipoprotein (a)'s association with platelets. Protein Pept Lett. 14:839-42 (2007) (Pubitemid 350013819)
34. MW Mosesson. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 8:1894-904 (2005) (Pubitemid 41716577)
35. R Testa, AR Bonfigli, C Sirolla, G De Grazia, P Compagnucci, S Manfrini, D Fumelli, I Testa. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications. Diabetes Nutr Metab. 5:269-75. (2000)
36. EM Salonen, O Saksela, T Vartio, A Vaheri, LS Nielsen, J Zeuthen. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J BiolChem. 260:12302-7. (1985) (Pubitemid 16228405)
37. S Stenman, K von Smitten, A Vaheri. Fibronectin and atherosclerosis. Acta Med Scand. 642:165-70 (1980)
38. M Woodward, A Rumley, P Welsh, S MacMahon, GA Lowe, Comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost. 9:1795-800 (2007) (Pubitemid 47288932)
39. A Imhof, D Rothenbacher, N Khuseyinova, A Hoffmeister, W Maerz, M Nauck, H Scharnagl, W Koenig, H Brenner. Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease. Eur J Cardiovasc Prev Rehabil. 5:362-70 (2003) (Pubitemid 38037251)
40. J Fan, T Watanabe. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb. 102:63-71 (2003)
41. JA Barnard, RM Lyons, HL Moses. The cell biology of transforming growth factor beta. Biochim Biophys Acta. 1032:79-87(1990).
42. MB Sporn, AB Roberts. TGF-beta: problems and prospects. CellRegul. 12:875-82 (1990)
43. R Derynck, JA Jarrett, EY Chen, DH Eaton, JR Bell, RK Assoian, AB Roberts, MB Sporn, DV Goeddel. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 316:701-5(1985) (Pubitemid 16239342)
44. JH Kehrl, AB Roberts, LM Wakefield, S Jakowlew, MB Sporn, AS Fauci. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol. 137:3855-60 (1986) (Pubitemid 17215314)
45. RL Heimark, DR Twardzik, SM Schwartz. Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science. 233:1078-80 (1986) (Pubitemid 16032237)
46. GK Owens, AA Geisterfer, YW Yang, A Komoriya. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol. 2:771-80 (1988)
47. S Stefoni, G Cianciolo, G Donati, A Dormi, MG Silvestri, L Coli, A De Pascalis, S Iannelli. Low TGF-betal serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int. 61:324-35 (2002) (Pubitemid 34075160)
48. N Bogavac-Stanojevic, S Djurovic, Z Jelic-Ivanovic, V Spasojevic-Kalimanovska, D Kalimanovska-Ostric. Circulating transforming growth factor-betal, lipoprotein(a) and cellular adhesion molecules in angiographically assessed coronary artery disease. Clin Chem Lab Med. 7: 893-8 (2003) (Pubitemid 37010181)
49. M Rath, A Niendorf, T Reblin, M Dietel, HJ Krebber, U Beisiegel. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 5: 579-92 (1989) (Pubitemid 19236892)
50. A Niendorf, M Rath, K Wolf, S Peters, H Arps, U Beisiegel, M Dietel. Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch A Pathol Anat Histopathol. 105-11. (1990) (Pubitemid 20204362)
51. Y Sato, R Tsuboi, R Lyons, H Moses, DB Rifkin. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol. 757-63. (1990)
52. S Kojima, PC Harpel, DB Rifkin. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 6:1439-45(1991) (Pubitemid 21909770)
53. S Allen, S Khan, S Tarn, M Koschinsky, P Taylor, M Yacoub. Expression of adhesion molecules by lp(a): a potential novel mechanism for its atherogenicity. FASEB J. 15:1765-76. (1998) (Pubitemid 28553672)
54. T Ichikawa, H Unoki, H Sun, H Shimoyamada, S Amrcovina, H Shikama, T Watanabe, J Fan. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am J Pathol. 227-36. (2002). (Pubitemid 34052283)
55. S Allen, S Khan, S Tarn, M Koschinsky, P Taylor, M Yacoub. Expression of adhesion molecules by lp(a): a potential novel mechanism for its atherogenicity. FASEB J. 15:1765-76. (1998) (Pubitemid 28553672)
56. S Takami, S Yamashita, S Kihara, M Ishigami, K Takemura, N Kume, T Kita, Y Matsuzawa. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation. 8:721-8(1998) (Pubitemid 28135333)
57. SP Zhao, DY Xu Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb Res. 6:501-10. (2000)
58. F Galvano, Li Volti G, Malaguarnera M Avitabile T, Antic T, Vacante M M Malaguarnera. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother. 10:1875-82.(2009)
59. W Patsch, AM Jr Gotto. Apolipoproteins: pathophysiology and clinical implications. Methods Enzymol. 263: 3-32 (1996) (Pubitemid 126691161)
60. M. Malaguarnera, I. Giugno, BA Trovato, MP Panebianco, N Restuccia, P Ruello. Lipoprotein(a) in cirrhosis. A new index of liver functions? Curr Med Res Opin. 13:479-85. (1996) (Pubitemid 26402691)
61. JH Stein, RS Rosenson. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med. 11: 1170-6 (1997) (Pubitemid 27251643)
62. M Motta, Giugno I, Bosco S., Pistone G, Ruello P, Maugeri D., M. Malaguarnera. Serum lipoprotein(a) changes in acute myocardial infarction. Panminerva Medica. 43:77-80. (2001) (Pubitemid 33636951)
63. Y Yano, K Shimokawa, Y Okada, A Noma. Immunolocalization of lipoprotein(a) in wounded tissues. J Histochem Cytochem. 4: 559-68 (1997) (Pubitemid 27175800)
64. J Thillet, C Doucet, J Chapman, E Herbeth, D Cohen, L Faure-Delanef. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians. Atherosclerosis. 2: 389-94 (1998) (Pubitemid 28133429)
65. G Pistone, AD Marino, C Leotta, S Dell'Arte, G Finocchiaro, M Malaguarnera. Levocarnitine administration in elderly subjects with rapid muscle fatigue - Effect on body composition, lipid profile and fatigue. Drugs Aging. 20:761-7. (2003) (Pubitemid 36995252)
66. M. Malaguarnera, Receputo G, Giugno I., Ruello P, Di Fazio I, M. Motta. Lipid profile in centenarians. Clin Drug Investig 11:240-244.(1996) (Pubitemid 26128910)
67. M. Malaguarnera, Ruello P, Rizzo M Receputo G, Rapisarda R, Restuccia N, G Pistone. Lipoprotein(a) levels in centenarians. Arch Gerontol Geriatr. Suppl. 5 385-8. (1996) (Pubitemid 26283580)
68. M Malaguarnera, I Giugno, P Ruello, M Rizzo, MP Panebianco, G Pistone, FB Tomasello. Lipid profile variations in a group of healthy elderly and centenarians. Eur Rev Med Pharmacol Sci. 2: 75-9 (1998) (Pubitemid 29173977)
69. DA Trégouét, IR König, J Erdmann, A Munteanu, PS Braund, AS Hall, A Grosshennig, P Linsel-Nitschke, C Perret, M DeSuremain, T Meitinger, BJ Wright, M Preuss, AJ Balmforth, SG Ball, C Meisinger, C Germain, A Evans, D Arveiler, G Luc, JB Ruidavets, C Morrison, P van der Harst, S Schreiber, K Neureuther, A Schäfer, P Bugert, NE El Mokhtari, J Schrezenmeir, K Stark, D Rubin, HE Wichmann, C Hengstenberg, W Ouwehand; Wellcome Trust Case Control Consortium; Cardiogenics Consortium, A Ziegler, L Tiret, JR Thompson, F Cambien, H Schunkert, NJ Samani. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 41:283-5. (2009)